A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Otsuka Pharmaceutical Co., Ltd.13 enrolled

Overview

ADPKD patients who were enrolled in Study 156-05-002 will receive repeated oral administration of OPC-41061 at doses of 15 mg twice daily (morning and evening). Administration will be continued until the time of manufacturing and distribution approval of OPC-41061 for ADPKD in Japan.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Autosomal Dominant Polycystic Kidney Disease

Interventions

OPC-41061DRUG

Repeated oral administration at doses of 15 mg twice daily (morning and evening)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients who completed 3-year repeated administrations and the follow-up observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (156-05-002) * Patients in whom adverse events occurring in study 156-05-002 were resolved or became stable and do not require further follow-up. Exclusion Criteria: * Patients with eGFR of less than 15 mL/min/1.73 m2 * Patients with any of the following complications: * Uncontrolled hypertension * Serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis) * Patients with any of the following complications or history thereof: * Clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity * Inability to personally give consent due to a mental illness

Locations (1)

Unnamed facility

Kanto Region, Japan

Outcomes

Primary Outcomes

Total Kidney Volume

Individual subject data on the volumes of the total kidney volume (sum of the volumes of the left and right kidneys) measured by magnetic resonance imaging or computed tomography during trial period. Repeated oral administration at doses of 15 mg twice daily (morning and evening) until approval of the revised protocol (Edition 4.0) by the IRB of each trial site. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame: Baseline, Week 48, 96, 144, and 192

Renal Function Test (eGFR)

Individual subject data on eGFR (estimated glomerular filtration rate calculated by Japanese eGFR equation) during trial period. Number of participants analyzed at each time point represents number of participants with data at the specified time point. Patients who were withdrawn from trial or have no appropriate data (e.g., interruption of medication, protocol deviation, etc.) are excluded.

Time frame: Baseline, Week 48, 96, 144, and 192

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.